KR20180008627A - 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법 - Google Patents

쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법 Download PDF

Info

Publication number
KR20180008627A
KR20180008627A KR1020177035970A KR20177035970A KR20180008627A KR 20180008627 A KR20180008627 A KR 20180008627A KR 1020177035970 A KR1020177035970 A KR 1020177035970A KR 20177035970 A KR20177035970 A KR 20177035970A KR 20180008627 A KR20180008627 A KR 20180008627A
Authority
KR
South Korea
Prior art keywords
sample
gra
fkbp5
subject
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177035970A
Other languages
English (en)
Korean (ko)
Inventor
조셉 케이. 빌래노프
헤이즐 헌트
존 프란시스 유니트
안드레아스 지. 모라이티스
Original Assignee
코어셉트 쎄라퓨틱스, 잉크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코어셉트 쎄라퓨틱스, 잉크. filed Critical 코어셉트 쎄라퓨틱스, 잉크.
Priority to KR1020247001601A priority Critical patent/KR102876869B1/ko
Publication of KR20180008627A publication Critical patent/KR20180008627A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177035970A 2015-05-18 2016-05-18 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법 Ceased KR20180008627A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247001601A KR102876869B1 (ko) 2015-05-18 2016-05-18 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562163130P 2015-05-18 2015-05-18
US62/163,130 2015-05-18
PCT/US2016/033143 WO2016187347A1 (en) 2015-05-18 2016-05-18 Methods for diagnosing and assessing treatment for cushing's syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001601A Division KR102876869B1 (ko) 2015-05-18 2016-05-18 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법

Publications (1)

Publication Number Publication Date
KR20180008627A true KR20180008627A (ko) 2018-01-24

Family

ID=57320595

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177035970A Ceased KR20180008627A (ko) 2015-05-18 2016-05-18 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법
KR1020247001601A Active KR102876869B1 (ko) 2015-05-18 2016-05-18 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247001601A Active KR102876869B1 (ko) 2015-05-18 2016-05-18 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법

Country Status (10)

Country Link
US (3) US10604807B2 (enExample)
EP (1) EP3297728A4 (enExample)
JP (3) JP6755264B2 (enExample)
KR (2) KR20180008627A (enExample)
AU (1) AU2016264321B2 (enExample)
CA (1) CA2984623C (enExample)
IL (2) IL309712A (enExample)
MX (1) MX2017014857A (enExample)
PH (1) PH12017502099B1 (enExample)
WO (1) WO2016187347A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195214B2 (en) 2017-03-01 2019-02-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
CN108389135A (zh) * 2018-03-21 2018-08-10 安徽理工大学 一种基于灰色关联模型的突水水源判别方法
CN113194957A (zh) * 2018-12-21 2021-07-30 科塞普特治疗公司 通过施用糖皮质激素受体调节剂治疗库欣综合征中的高凝血病
EP4157276A4 (en) 2020-05-27 2024-06-12 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
EP4157275A4 (en) * 2020-05-27 2024-06-05 Corcept Therapeutics Incorporated CONCURRENT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACTORILANTS AND CYP2C8 SUBSTRATES
MX2022014923A (es) * 2020-05-27 2023-01-04 Corcept Therapeutics Inc Administracion concomitante del modulador del receptor de glucocorticoides relacorilant y sustratos cyp2c9.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
JP2004526425A (ja) * 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
EP1616026A1 (en) * 2003-04-14 2006-01-18 Novartis AG Gene expression associated with osteoblast differentiation
CA2736626C (en) * 2008-09-12 2022-12-06 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Genes associated with posttraumatic-stress disorder (ptsd)
US8940705B2 (en) * 2009-01-09 2015-01-27 The Regents Of The University Of California Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
JP2013090761A (ja) 2011-10-25 2013-05-16 Osaka City Univ 立体視内視鏡装置
NZ701469A (en) 2012-05-25 2017-06-30 Corcept Therapeutics Inc Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US20140170768A1 (en) 2012-12-14 2014-06-19 Joel R. L. Ehrenkranz Method for monitoring and assessing pituitary function

Also Published As

Publication number Publication date
EP3297728A4 (en) 2019-07-03
JP2020195401A (ja) 2020-12-10
KR102876869B1 (ko) 2025-10-27
JP6755264B2 (ja) 2020-09-16
AU2016264321B2 (en) 2021-02-18
US11268145B2 (en) 2022-03-08
US20180100179A1 (en) 2018-04-12
PH12017502099A1 (en) 2018-05-07
CA2984623A1 (en) 2016-11-24
US10604807B2 (en) 2020-03-31
AU2016264321A1 (en) 2017-11-30
KR20240014584A (ko) 2024-02-01
WO2016187347A1 (en) 2016-11-24
PH12017502099B1 (en) 2023-08-30
EP3297728A1 (en) 2018-03-28
JP2020079799A (ja) 2020-05-28
JP2018524562A (ja) 2018-08-30
US20200216905A1 (en) 2020-07-09
IL309712A (en) 2024-02-01
IL255612A (en) 2018-01-31
US20180291451A1 (en) 2018-10-11
MX2017014857A (es) 2018-08-15
CA2984623C (en) 2023-05-02
JP6893264B2 (ja) 2021-06-23

Similar Documents

Publication Publication Date Title
Stowasser et al. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney
Tucci et al. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
JP6893264B2 (ja) クッシング症候群についての処置を診断および評価するための方法
Brouwer et al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression
WO2017007941A2 (en) Compositions and methods for identification, assessment prevention, and treatment of cancer using slncr isoforms
WO2018223867A1 (zh) 一种前列腺癌的标志物spop及其在指导肿瘤治疗中的应用
Min et al. The decline of whole-body glucose metabolism in ovariectomized rats
WO2017223344A1 (en) Transdifferentiation as a mechanism of treatment resistance for castration-resistant prostate cancer
US20230220480A1 (en) Iron-score and in vitro method for identifying high risk dlbcl subjects and therapeutic uses and methods
CN117947156A (zh) Ptbp2在神经母细胞瘤预后评估中的应用
Nicolaides et al. Transcriptomics in tissue glucocorticoid sensitivity
WO2012021942A1 (en) Tam receptors and tam receptor ligands in detection and modulation of neuropathological disease
Zhao et al. Different cell compositions and a novel somatic KCNJ5 variant found in a patient with bilateral adrenocortical adenomas secreting aldosterone and cortisol
Cucuzza et al. Role of FKBP51 in the modulation of the expression of the corticosteroid receptors in bovine thymus following glucocorticoid administration
US20130324508A1 (en) Biomarker for prostate cancer and method of using the same
US20070254303A1 (en) Methods for assessing the efficacy of treatment with a glucocorticoid
Rossi et al. Does angiotensin II regulate parathyroid hormone secretion or not?
Sasaki et al. Case report of familial Carney complex due to novel frameshift mutation c. 597del C (p. Phe200LeufsX6) in PRKAR1A
Tziraki et al. Reduction in glucocorticoid receptors in renal biopsies of patients with lupus nephritis
Zhou et al. SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes
Curtin et al. Lean breast adipocytes secrete an oxylipin that suppresses breast cancer via ferroptosis
WO2017211983A1 (en) Methods using blm as a marker of multiple myeloma
Taylor Inflammatory Gene Expression in Women Diagnosed with Polycystic Ovarian Syndrome
EP4069213A1 (en) Cyclooxygenase-2 inhibition for the treatment of saa-high asthma
Pollock Evaluation of novel glucocorticoid receptor ligand activity in skeletal muscle cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000